Repositioning Drugs for Cancer Gliomas

Dear Colleagues,

Gliomas account for more than 70% of malignant brain tumors. Archetypal glial tumors known to involve glial cell dysregulation include: (i) astrocytomas, the most common glioma developing from astrocytes, (ii) oligodendrogliomas, derived from oligodendrocytes and (iii) glioblastoma multiforme, the most invasive/aggressive brain cancer involving astrocytes and oligodendrocytes.

Unfortunately, these cancers are poorly served by therapeutic treatment. This remains the case, despite astrocytes and oligodendrocytes being well studied, with existing marketed drugs known alter their cell function by engagement of the receptors these cells express.

We consider that the repositioning of current marketed drugs or drugs in development known to regulate astrocyte or oligodendrocyte biology, or by drugs known to regulate receptors expressed on these glial cells are worthy of study in astrocytomas, oligodendrogliomas and glioblastoma multiforme.

In this Special Issue of Cancers, here coin and introduce the phrase Redcangliomics (repositioning drugs for cancer gliomas) and cover new research articles and timely reviews on therpies that regulate astrocyte and oligodendrocyte biology and that have potential utility in the management of patients with the cancers associated with astrocytes and oligodendrocytes.

Prof. Kumlesh Kumar Dev
Dr. Melissa J. Conroy
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.